Patents by Inventor Terri Lynn Davis-Smyth

Terri Lynn Davis-Smyth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of inhibiting vascular endothelial growth factor activity
    Patent number: 9273113
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: March 1, 2016
    Assignee: GENENTECH, INC.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    Publication number: 20130178418
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: August 13, 2012
    Publication date: July 11, 2013
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Inhibitors of vascular endothelial growth factor activity
    Patent number: 8273353
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 25, 2012
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Compositions and methods for producing inhibitors of vascular endothelial growth factor activity
    Patent number: 8268591
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 18, 2012
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Methods for using inhibitors of vascular endothelial growth factor activity
    Patent number: 8268313
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 18, 2012
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    Publication number: 20110300577
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: April 28, 2011
    Publication date: December 8, 2011
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    Publication number: 20110300578
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: April 28, 2011
    Publication date: December 8, 2011
    Inventors: Terri Lynn Davis-Smyth, Helen Heifel Chen, Leonard Presta, Napoleone Ferrara
  • NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    Publication number: 20110301337
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: April 28, 2011
    Publication date: December 8, 2011
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    Publication number: 20110301338
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: April 28, 2011
    Publication date: December 8, 2011
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    Publication number: 20110301339
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: April 28, 2011
    Publication date: December 8, 2011
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    Publication number: 20110213130
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: April 28, 2011
    Publication date: September 1, 2011
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Methods for using chimeric vascular endothelial growth factor receptor proteins
    Patent number: 7771721
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and anglogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: August 10, 2010
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION
    Publication number: 20090234103
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: April 17, 2008
    Publication date: September 17, 2009
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • METHODS FOR USING CHIMERIC VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR PROTEINS
    Publication number: 20090010933
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and anglogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: April 17, 2008
    Publication date: January 8, 2009
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
    Patent number: 6897294
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: May 24, 2005
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
    Publication number: 20030092604
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: March 20, 2002
    Publication date: May 15, 2003
    Applicant: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
    Patent number: 6383486
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: May 7, 2002
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
    Patent number: 6100071
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: May 7, 1996
    Date of Patent: August 8, 2000
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production
    Patent number: 5952199
    Abstract: The present invention is directed to novel VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1, FLT4, and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: September 14, 1999
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara